Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma.
- Author:
Wenhua LI
;
Qi SUN
;
Meiying LU
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Carcinoma;
Cisplatin;
therapeutic use;
DNA-Binding Proteins;
biosynthesis;
Endonucleases;
biosynthesis;
Humans;
Lung Neoplasms;
secondary;
Nasopharyngeal Carcinoma;
Nasopharyngeal Neoplasms;
drug therapy;
metabolism;
pathology
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(2):144-146
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the expression of excision repair cross-complementing 1 (ERCC1) and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma (NPC).
METHOD:The expression of ERCC1 protein in 107 cases with NPC and in 48 normal nasopharyngeal tissues adjacent to the cancer was detected by immunohistochemical method.
RESULT:High expression of ERCC1 was observed in 52 cases with NPC, and 18 cases normal nasopharyngeal tissues, there was no statistically significant differences between them. The expression of ERCC1 protein was significant correlated with patient total TNM stage, but not significantly correlated with age, gender, histological type, T stage and N stage. The recent treatment efficiency in Low ER-CCl expression cases was higher than high expression cases. There was statistically significant difference between them. In 97 follow-up cases, 2 cases died, 5 cases with liver and lung metastasis, there was no statistically significant difference between them.
CONCLUSION:ERCC1 expression maybe regarded as indicator platinum based chemotherapy sensitivity prediction in nasopharyngeal carcinoma, and also helpful for formulating individualized treatment. The immunohistochemical detection is also simple and effective detection method for ERCC1 expression.
